Tag: Cordis

Cordis Continues to Expand Interventional Cardiology Portfolio with Radial Offering

DUBLIN, Ohio, May 14, 2019 /PRNewswire/ — Cordis, a Cardinal Health company, recently announced the full U.S. launch of its RADIAL 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for interventional cardiology procedures. The transradial approach uses the radial artery in the wrist to access the body’s […]

Cardinal Health Announces FDA Approval of the INCRAFT® AAA Stent Graft System

DUBLIN, Ohio, November 28, 2018 — Cordis, a Cardinal Health company (NYSE: CAH), today announced that the U.S. Food and Drug Administration (FDA) has approved its INCRAFT® AAA Stent Graft System for use in complex access anatomies. The INCRAFT system is an ultra-low profile and flexible endovascular aneurysm repair (EVAR) system designed […]

Cordis/Medinol DES implanted in the U.S.

N.Y. Presbyterian/Columbia implant EluNIR stent Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ Drug-Eluting Stent – by CardiovascularBusiness DUBLIN, Ohio, January 11, 2018 — Cordis, a Cardinal Health company, and Medinol today announced that the first commercial cases using the EluNIR™ drug-eluting stent (DES) in the United States […]

Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

DUBLIN, Ohio, Nov. 30, 2017 /PRNewswire/ — Cordis, a Cardinal Health company, and Medinol today announced United States Food and Drug Administration (FDA) approval of the EluNIR™ drug-eluting stent (DES) for the treatment of patients with narrowing or blockages to their coronary arteries. The EluNIR™ stent system is designed with a novel metallic […]

Cordis, a Cardinal Health Company, introduces innovative products at EUROPCR 2017 to rapidly expand interventional cardiology offering

PCRonline/News/Industry Press Releases – 15 May, 2017 DUBLIN, Ohio. Cordis, Cardinal Health‘s interventional vascular business, announced today the commercial launch of three new products that further enhance its interventional cardiology product portfolio in Europe, the Middle East, and Africa (EMEA). The addition of the Cordis RAILWAY Sheathless Access System as well […]

NEWS RELEASE Biosensors Announces Enrollment of the First American Patient in the new US Pivotal BioFreedom Trial – “LEADERS FREE II”

Press Release Singapore, 22 March 2017 – Biosensors International Group, Ltd. (“Biosensors” or the “Company”), a developer, manufacturer and marketer of innovative medical devices, announced today the enrollment of the first American patient in LEADERS FREE II, its new BioFreedom Pivotal Study, conducted under an Investigational Device Exemption (IDE), which […]